Bruno Medeiros
Key Documents
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr CC2329 MC 5821 Stanford, CA 94305 Tel Work (650) 498-5000 Fax (650) 724-5203
Professional Overview
Clinical Focus
- Cancer> Hematology
- Hematology
- Acute leukemia
Administrative Appointments
- Director, Stanford Hospital Hematology Inpatient service (2011 - 2012)
- Director, Stanford Acute Leukemia Clinical Research Program (2009 - 2012)
- Panel member adult oncology committee, National comprehensive cancer network (2010 - 2012)
- Acute Leukemia Panel Member, Southwest Oncology Group (SWOG) (2007 - 2012)
- Panel Member Multiple Myeloma Committee, National Comprehensive Cancer Network (2007 - 2011)
Professional Education
| Board Certification: | Hematology, American Board of Internal Medicine (2006) |
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2005) |
| Fellowship: | University of Colorado Health Science Center CO (2005) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2002) |
| Residency: | University of Colorado Health Science Center CO (2002) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
My clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia.
Clinical Trials
- Phase I/II Combination 5-azacitidine and Gemtuzimab Ozogamycin for Relapsed AML Recruiting
- Phase II Azacitidine + Lenalidomide combo in the elderly previously treated AML & High-Risk MDS Recruiting
- Phase II Clofarabine with High Dose Cytarabine and G-CSF Priming in New Dx AML or Advanced MDS Recruiting
- Phase Ib Panobinostat +/-Idarubicin &Cytarabine Induction &High-Dose Cytarabine-Based Therapy in AML Recruiting
- Single Agent Lenalidomide in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Recruiting
Publications
- Blood consult: monosomal karyotype acute myeloid leukemia. Blood. 2012
- Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia. Haematologica. 2012
- Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. Am J Hematol. 2012; (1): 45-50
- Unveiling the complexity of CK+ AML. Blood. 2012; (9): 1958-9
- Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011; (22): 2167-8; author reply 2168-9
Help